Investorideas.com newswire, breaking stock news, business news and commentary for marijuana sector

Monday, April 24, 2017

Lemonhaze.com Reports WA Retail Marijuana Sales Spike 79% on 4/20

Lemonhaze.com Reports WA Retail Marijuana Sales Spike 79% on 4/20


SEATTLE - April 24, 2017 (Investorideas.com Newswire) Lemonhaze.com, the leading real-time provider of cannabis data, released live market data for April 20, 2017, the de facto "black Friday of the cannabis market." "April 20th is the fourth biggest sales day of the year for Washington marijuana retailers behind only New Year's Eve, Christmas Eve, and the day before Thanksgiving," remarked Brian Yauger, president of lemonhaze.com.
For April 20, 2017, lemonhaze.com calculated a 79 percent jump in daily sales revenue, compared to the average daily sales for the first 19 days of April. Lemonhaze also calculated a 73 percent jump in daily sales compared to the average Thursday in 2017. "420 was a monster success this year. We had all hands on deck and still barely kept up with it. It's the best holiday of the year," according to Alden Linn, owner of World of Weed retail shop in Tacoma.
Recreational marijuana is one of the fastest-growing industries in the county. Currently Washington State has 365 active retailers compared to 251 this time last year. In the last year, there has been a 45 percent increase in the number of cannabis retail stores in Washington, and a 61 percent increase in sales between April 20, 2016 and April 20, 2017.
According to retail owner Ian Eisenberg of Uncle Ike's, Washington's second largest retailer in 2016, "420 was bonkers! Two years ago, it was primarily pot heads celebrating 420. This year it was moms, dads, grannies and everyone else excited about getting high! God bless America!"
About Lemonhaze.com
Lemonhaze.com publishes hourly live charts of the top selling cannabis products in Washington State across nine categories including packaged flower, pre-rolls, cartridges and edibles. The charts lock at 4:20pm each day. Lemonhaze.com sources information via live data connections with well over 100 licensed cannabis retailers, processors, and producers in Washington State.
Contacts
Lemonhaze.com
Brian Yauger
206-305-8796
brian@lemonhaze.com
Marijuana / Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Global Cannabis Investing - features Investor Ideas Cannabis news



Watch the 420 Cannabis Investor video
 

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Medical Marijuana Stock News; Cronos Group (TSX VENTURE: $MJN) Provides Update on Minority Investments

Medical Marijuana Stock News; Cronos Group (TSX VENTURE: $MJN) Provides Update on Minority Investments


TORONTO, ON - April 24, 2017 (Investorideas.com Newswire) Cronos Group Inc. (formerly PharmaCan Capital Corp.) (TSX VENTURE: MJN) ("Cronos", or the "Company") is providing an update on its investments in Whistler Medical Marijuana Corporation ("Whistler"), The Hydropothecary Corporation ("Hydropothecary"), ABcann Medicinals Inc. ("ABcann"), Evergreen Medicinal Supply Inc. ("Evergreen"), and CannMart Inc. ("CannMart").
Whistler
As previously announced, Cronos recently completed its additional equity investment in Whistler and maintained the Company's 21.5% equity position. This additional capital will assist Whistler with their announced 65,000 square foot expansion in Pemberton, British Columbia. This expansion is expected to be completed by spring of 2018 in advance of recreational legalization in Canada.
Hydropothecary
Cronos holds a minority equity position in Hydropothecary, which recently started trading on the Toronto Venture Exchange on March 21st, 2017 under the symbol "THCX". Hydropothecary is the only licensed producer in Quebec and is currently operating and expanding on its 80 acres of land near Gatineau, QC.
ABcann
ABcann recently announced a reverse takeover with Panda Capital Inc., which shall constitute ABcann's qualifying transaction. ABcann is licensed to produce up to 625 kg per year at their flagship Vanluven facility situated near Napanee, ON. Abcann recently supplemented its executive and advisory teams and undertook significant expansion initiatives at both their existing licensed facility as well as their expansion property.
Evergreen
Cronos completed its subscription for a second tranche of shares of Evergreen for $100,000 and exercised its option to acquire an additional 5% of the equity for $500,000, for a total additional investment of $600,000. Cronos satisfied this obligation in part by directing that debt owed by Evergreen be applied as payment for the equity and delivered the remainder of the payment in cash. However, Evergreen claims that Cronos is not entitled to any interest in Evergreen and has rejected Cronos' payment.
Cronos filed a statement of claim in the Supreme Court of British Columbia and intends to vigorously pursue the enforcement of its rights to acquire equity in Evergreen in addition to Evergreen's repayment of the debt. While there can be no assurance that Cronos will acquire its equity in Evergreen, management believes that Cronos is entitled to the relief sought in its statement of claim.
CannMart
Cronos no longer intends to retain an investment in CannMart and CannMart has agreed to return the $25,000 previously paid by Cronos in respect of its proposed equity investment in CannMart.
About Cronos Group
Cronos Group, is a geographically diversified and vertically integrated cannabis company that operates two wholly-owned Licensed Producers ("LPs") regulated within Health Canada's Access to Cannabis for Medical Purposes Regulations (the "ACMPR") and holds a portfolio of minority investments in other Licensed Producers. The company's flagship LPs, Peace Naturals Project Inc. (Ontario), and In The Zone Produce Ltd. (British Columbia) are collectively situated on over 125 acres of agricultural land and are currently licensed to produce 2,600 kg of cannabis on an annual basis. The Company also holds minority equity positions in Licensed Producers Whistler Medical Marijuana, Hydropothecary, and Abcann. Cronos Group is focused on building an iconic brand portfolio, providing patients with compassionate and personalized care, and creating value for our shareholders.
Forward-looking statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian securities legislation. All information contained herein that is not clearly historical in nature may constitute forward-looking information. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive risks, uncertainties and contingencies that may cause actual financial results, performance or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by those forward-looking statements and the forward-looking statements are not guarantees of future performance. Except as required by law, Cronos Group disclaims any obligation to update or revise any forward-looking statements. Readers are cautioned not to put undue reliance on these forward-looking statements. This news release contains information obtained by Cronos Group from third parties. Cronos Group believes such information to be accurate but has not independently verified such information.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information, please visit www.thecronosgroup.com.
Contact:
Michael Krestell
Investor & Media Relations
TEL: 647-274-3655
E-mail: michael@thecronosgroup.com
Marijuana / Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Global Cannabis Investing - features Investor Ideas Cannabis news



Watch the 420 Cannabis Investor video
 

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


#Cannabis Experts Join True Leaf (CSE: $MJ) (FSE: $TLA) Team for Final Marijuana Licensing Review Stage

#Cannabis Experts Join True Leaf (CSE: $MJ) (FSE: $TLA) Team for Final Marijuana Licensing Review Stage
Experts will advise on production facility design and build, security, and product testing before pre-license inspection

Vancouver, British Columbia - April 24, 2017 (Newsfile Corp.) (Investorideas.com Newswire) True Leaf Medicine Inc. (True Leaf), a division of True Leaf Medicine International Ltd. (CSE: MJ) (FSE: TLA), has engaged a number of cannabis experts to guide the company through the final stage in Health Canada's review of its application for a license to produce marijuana in Canada.
Experts from industry-leading Pipe Dreemz Inc., Protect-IP Global Solutions Inc., Eurofins Scientific, and Ample Organics will be working with True Leaf over the next few weeks to prepare a review package for submission to Health Canada under the Access to Cannabis for Medical Purposes Regulations (ACMPR) application process.
Health Canada recently upgraded the Marihuana for Medical Purposes Regulations (MMPR) application process to the ACMPR licensing program, so the experts will be working with True Leaf to update its original MMPR application to ensure True Leaf meets or exceeds the new compliance measures.
"True Leaf is excited to have Pipe Dreemz, Protect-IP, Eurofins, and Ample Organics provide their expertise at this critical stage in the ACMPR review process," said True Leaf CEO Darcy Bomford. "We sought out experts from these companies because several of their clients have already been successful in the ACMPR process."
True Leaf has engaged Pipe Dreemz CEO George Routhier, a premier consultant to companies going through Health Canada's Marihuana for Medical Purposes Regulations (MMPR) or ACMPR process since 2012. Mr. Routhier helps his clients navigate the complexities of the licensing process, specifically the design, construction, and operating procedures of marijuana production facilities. Pipe Dreemz is currently advising clients with over $150 million in production facilities under construction in Canada.
Protect-IP will advise True Leaf on the Physical Safety Integration of its planned production facility. Protect-IP's engineering team has worked with companies in all phases of the licensing process, and will work with True Leaf on developing procedures for control systems, alarm systems, and CCTV using IP technology to ensure True Leaf builds and operates a safe and secure production facility.
Eurofins, a leading international group of laboratories with more than 22,000 employees across 225 sites in 39 countries, will help True Leaf test its marijuana products to ensure it complies with Health Canada regulations. Eurofins works with the pharmaceutical, food, environmental, and consumer products industries on a wide-range of scientific testing and support services.
True Leaf has also engaged Ample Organics, the most widely adopted seed-to-sale reporting system among Canada's licensed marijuana producers.
"We are pleased to be working with True Leaf, a late stage ACMPR applicant," said Pipe Dreemz CEO George Routhier. "Darcy and his team have chosen to accelerate their final push to the finish line, and together we expect to receive their pre-license inspection in the very near future."
About True Leaf:
True Leaf Medicine International Ltd., through its wholly-owned subsidiary 'True Leaf Pet', has entered the $104.9 billion global pet care industry with a line of hemp-focused pet chews and supplements marketed through natural pet health and veterinary channels in Canada, the United States and Europe. The company has also filed an application under Health Canada's Access to Cannabis for Medical Purposes Regulations (ACMPR) to become a Canadian licensed producer through its 'True Leaf Medicine' subsidiary. It has passed through the security screening process of Health Canada's review and is currently in the final review stage before the 'pre-licensing inspection' approval.
Media Contact:
Paul Sullivan
BreakThrough Communications
p.sullivan@breakthroughpr.com
O: 604-685-4742
M: 604-603-7358
Investor Contact:
Kevin Bottomley
Director and Corporate Relations
kevin@trueleaf.com
M: 778-389-9933
Marijuana / Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Global Cannabis Investing - features Investor Ideas Cannabis news



Watch the 420 Cannabis Investor video
 

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Friday, April 21, 2017

Investorideas.com Listed on The Canadian Securities Exchange (CSE) Directory of Service Providers

Investorideas.com Listed on The Canadian Securities Exchange (CSE) Directory of Service Providers

April 21, 2017 (Investorideas.com Newswire) http://thecse.com/ Reports The common shares of Maricann Group Inc. have been approved for listing on the CSE.


Listing and disclosure documents will be available at www.thecse.com
Maricann Group Inc. is a vertically integrated medical marijuana company operating a cultivation, extraction and distribution business.
L’inscription à la cote de CSE des actions ordinaires de Maricann Group Inc. a été approuvée.
Les documents d'inscription et de divulgation seront disponibles sur www.thecse.com
Maricann Group Inc. est une entreprise intégrée verticalement dans le secteur de la culture, l’extraction et distribution de marijuana médicale.


Contact Listings at (416) 367-7340 or E-mail: Listings@thecse.com
About the CSE
The Canadian Securities Exchange, or CSE, is operated by CNSX Markets Inc. Recognized as a stock exchange in 2004, the CSE began operations in 2003 to provide a modern and efficient alternative for companies looking to access the Canadian public capital markets. www.thecse.com


More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Vermont Senate Approves Bill to Regulate #Marijuana for Adult Use and Eliminate Penalties for Home Cultivation

Vermont Senate Approves Bill to Regulate #Marijuana for Adult Use and Eliminate Penalties for Home Cultivation
Statement below from Matt Simon of the Marijuana Policy Project

MONTPELIER, Vt. - April 21, 2017 (Investorideas.com Newswire) The Vermont Senate approved a bill on Friday that would regulate the production and sale of marijuana and eliminate penalties for personal possession and cultivation by adults 21 and older.
The Senate amended H. 167, an unrelated House-approved bill, to replace it with a revised version of a marijuana regulation bill that passed last year in the Senate and failed in the House. The Senate also amended H. 167 to include the same home cultivation provision that is included in H. 170, a bill that has been making its way through the House. H. 170 would eliminate Vermont's civil penalty for possessing one ounce or less of marijuana and remove penalties for possession of up to two mature marijuana plants and up to four immature plants. The Senate proposal would allow unlimited small-scale cultivation licenses for producers no larger than 500 sq feet. The marijuana regulation bill that failed in the House last year, S. 241, did not include a home cultivation provision.
The Senate-amended version of H. 167 will receive one final vote before being sent back to the House for consideration.
Most Vermont voters are in favor of the policy changes proposed in H. 167 and H. 170, according to a survey conducted March 20-21 by Public Policy Polling. Fifty-seven percent support allowing adults 21 and older to possess and grow limited amounts of marijuana, and 54% support regulating and taxing marijuana similarly to alcohol. The results are available at https://www.mpp.org/VTpoll.
Statement from Matt Simon, New England political director for the Marijuana Policy Project:
"Most Vermonters think marijuana should be made legal for adults, and they're looking to lawmakers to come up with a plan. We applaud the Senate for approving a thoughtful alternative to marijuana prohibition that would account for public health and improve public safety. We would love to see the House step up and join the Senate in supporting this sensible reform. If the House isn't willing to support the Senate's proposal, it at least needs to support its own Judiciary Committee's plan and pass H. 170."
The Vermont Coalition to Regulate Marijuana is a broad coalition of citizens, organizations, and businesses working to end marijuana prohibition in Vermont and replace it with a system in which marijuana is regulated and taxed. For more information, visit http://www.RegulateVermont.org.
Contact
Matt Simon
603-391-7450, msimon@mpp.org


Marijuana / Hemp Stocks
Like Marijuana Stocks? View our Marijuana / Hemp Stocks Directory
Global Cannabis Investing - features Investor Ideas Cannabis news



Watch the 420 Cannabis Investor video
 

More Info:

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


This Week’s Cannabis and Hemp Stocks Added; $DVA.V; $SVSN

This Week’s Cannabis and Hemp Stocks Added; $DVA.V; $SVSN

Other New Marijuana/Hemp Stocks: ASX: ZLD, BOT, CPH, MDC



Point Roberts, WA, Delta BC – April 21, 2017 – Investorideas.com, a global news source and investor resource covering actively traded sectors announces this week’s additions to its cannabis /hemp stock directory for investors following the sector.

Australian listed (ASX) stocks are at the forefront of this week’s additions with 4 new stocks being added that include a company involved in medical cannabis for treatment of a variety of ailments; a cannabis-based medicine for oncology; cannabidiol treatment for psoriasis and atopic dermatitis and Creso Pharma Limited (ASX:CPH.AX) a leader in cannabidiol (CBD) innovation, currently developing cannabis and hempderived therapeuticgrade Nutraceuticals and Medical Cannabis products with a broad range of applications in both human and animal health.

Also new this week are Delivra Corp. (TSX:DVA.V) is a specialty biotechnology company who recently completed a strategic partnership with Dosecann Inc. and ARA-Avanti RX Analytics Inc. to develop a unique suite of standardized and commercialized products for the medical cannabis market and Stereo Vision Entertainment, Inc. (OTC:SVSN) a media company who is also the majority owner of medical cannabis and organic hemp subsidiary, MediCannaVision Inc., dba CannaVision.

Investorideas.com cannabis/marijuana and hemp content now includes: http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the AI site  Global Cannabis Investing at www.Globalcannabisinvesting.com





New Marijuana Companies Added to the Investor cannabis stock directory:

Botanix Pharmaceuticals Ltd. (ASX:BOT.AX) mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. We are harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

Creso Pharma Limited (ASX:CPH.AX) pharmaceutical expertise and methodological rigour to the world of medical cannabis and strives for the highest quality in its products, leveraging science and research in order to develop, register and commercialise innovative therapeutic approaches targeting the endocannabinoid system. Creso Pharma is a leader in cannabidiol (CBD) innovation, developing cannabis- and hempderived therapeuticgrade Nutraceuticals and Medical Cannabis products with a broad range of applications in both human and animal health. Creso Pharma’s innovative CBD fully plant-based nutraceutical products are non-psychoactive, as they contain only trace amounts of THC. Focusing on unique and innovative product delivery systems, Creso Pharma is developing therapeutic products and nutraceuticals manufactured according to the highest GMP standards, and maintaining the highest levels of compliance across the supply chain. Creso Pharma holds worldwide rights for a number of proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. Furthermore, Creso Pharma’s standardised dosage forms are specifically designed and adapted for human health and for animal health, and for several medical conditions including pain and anxiety disorders, metabolic disorders and inflammatory disorders.

Delivra Corp. (TSX:DVA.V) is a specialty biotechnology company that has a proprietary transdermal delivery system platform that can shuttle pharmaceutical and natural molecules, through the skin, in a targeted specific manner. Delivra manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport™ brand for sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and on-line at www.livrelief.com. LivRelief™ pain and nerve pain products are also available in the United States on Amazon and at www.livrelief.com/us. In parallel with its consumer products business, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the repurposing of pharmaceutical molecules transdermally to treat a broad range of conditions, along with licensing its over-the-counter products globally. Delivra is headquartered in Burlington, Ontario and has a research and development laboratory in Charlottetown, PEI. Cannabis: Completed a strategic partnership with Dosecann Inc. and ARA-Avanti RX Analytics Inc. to develop a unique suite of standardized and commercialized products for the medical cannabis market

Medlab Clinical Ltd. (ASX:MDC.AX) l is an Australian based medical life science company, with a certified biologics facility in Sydney and sales arms in Australia and California. Medlab’s research relates to five health areas - obesity, chronic kidney disease, depression, ageing and muscular skeletal health and pain management. A lot of Medlab’s research is on the role bacteria in the gastrointestinal tract play in health and disease, leading to drug discovery and development of new medicines involving bacteria (pharmacobiotics) as well as nutritional products. Medlab is also about to commence a human trial of a cannabis-based medicine for oncology patients with intractable pain, utilising its small particle medicine delivery system, Nanocelle™. Medlab has a growing patent portfolio, multiple published research papers and conference presentations and the Pharmacobiotic trademark – a therapeutic term referring to both probiotics and biologics.

Stereo Vision Entertainment, Inc. (OTC:SVSN) is a publicly traded Nevada company focused on creating, acquiring, and producing multimedia content with its media subsidiaries the majority owned family entertainment company Inspirational Vision Media and the wholly owned 9 time Emmy Award winning production company REZN8, and the majority owned medical cannabis and organic hemp subsidiary, MediCannaVision Inc., dba CannaVision.

Zelda Therapeutics Limited (ASX:ZLD.AX) has been formed to bring together some of the world’s leading researchers and clinicians active in the study and use of medicinal cannabis to treat a variety of ailments.

The complete marijuana/hemp stock list available for purchase in a PDF format:

Investorideas.com tracks companies in high profile trading sectors and makes ongoing additions to its stock directories for each sector.  Listing for the stock directories include companies on the TSX, OTC, NYSE, NASDAQ and global stock exchanges.

Investorideas.com global stock directories are part of the membership program on the site, accessed either by login and password or available in PDF format.  The directories include stocks trading on the TSX, OTC, NASDAQ, NYSE and other recognized global stock exchanges, giving retail investors a wide variety of stocks to review. http://www.investorideas.com/membership/

The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, podcasts, company profiles, interviews and more in leading sectors.

Sectors we cover include tech, bitcoin and blockchain, biotech, mining, energy, renewable energy, water stocks, marijuana and hemp stocks, food and beverage (including organic and LOHAS, wine), defense and security (including biometrics), Latin America, sports, entertainment, luxury brands and gaming.

The Investorideas.com content portfolio goes beyond the www.investorideas.com site to include 12 blogs on Blogger.com, 7 Artificial Intelligence (AI) websites on the Grid and the Waternewswire.com, all featuring Investorideas.com news and content.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Services for Publicly traded and private companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution,social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com
800-665-0411


Marijuana / Hemp Stocks

Like Marijuana / Hemp Stocks? View our Marijuana / Hemp Stocks Directory
Global Cannabis Investing - features Investor Ideas Cannabis news